JP2009510064A - 神経障害、精神障害または疼痛性障害の処置用の新規化合物 - Google Patents

神経障害、精神障害または疼痛性障害の処置用の新規化合物 Download PDF

Info

Publication number
JP2009510064A
JP2009510064A JP2008533434A JP2008533434A JP2009510064A JP 2009510064 A JP2009510064 A JP 2009510064A JP 2008533434 A JP2008533434 A JP 2008533434A JP 2008533434 A JP2008533434 A JP 2008533434A JP 2009510064 A JP2009510064 A JP 2009510064A
Authority
JP
Japan
Prior art keywords
disease
pain
use according
disorder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008533434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510064A5 (OSRAM
Inventor
ミニディス，アレクサンダー
ウェンスボ，デイヴィッド
スラッシ，アブデルマリック
アイザック，メスヴィン
エリックソン，キャロライン
プロフィア，ベロニカ
バーグストロム，パー−オロブ
エドワーズ，ルイーズ
アロラ，ジャライ
ジン，タオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2009510064A publication Critical patent/JP2009510064A/ja
Publication of JP2009510064A5 publication Critical patent/JP2009510064A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
JP2008533434A 2005-09-29 2006-09-20 神経障害、精神障害または疼痛性障害の処置用の新規化合物 Pending JP2009510064A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72152705P 2005-09-29 2005-09-29
PCT/US2006/036423 WO2007040982A1 (en) 2005-09-29 2006-09-20 5- (phenylisoxazolylethoxy) -triazol- 3 -yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009211258A Division JP2010013476A (ja) 2005-09-29 2009-09-14 神経障害、精神障害または疼痛性障害の処置用の新規化合物

Publications (2)

Publication Number Publication Date
JP2009510064A true JP2009510064A (ja) 2009-03-12
JP2009510064A5 JP2009510064A5 (OSRAM) 2009-11-05

Family

ID=37745801

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008533434A Pending JP2009510064A (ja) 2005-09-29 2006-09-20 神経障害、精神障害または疼痛性障害の処置用の新規化合物
JP2009211258A Pending JP2010013476A (ja) 2005-09-29 2009-09-14 神経障害、精神障害または疼痛性障害の処置用の新規化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009211258A Pending JP2010013476A (ja) 2005-09-29 2009-09-14 神経障害、精神障害または疼痛性障害の処置用の新規化合物

Country Status (18)

Country Link
US (4) US7476684B2 (OSRAM)
EP (1) EP1934209A1 (OSRAM)
JP (2) JP2009510064A (OSRAM)
KR (1) KR20080050421A (OSRAM)
CN (1) CN101273037A (OSRAM)
AR (1) AR058807A1 (OSRAM)
AU (1) AU2006297462A1 (OSRAM)
BR (1) BRPI0616228A2 (OSRAM)
CA (1) CA2623009A1 (OSRAM)
EC (1) ECSP088283A (OSRAM)
IL (1) IL189990A0 (OSRAM)
NO (1) NO20081434L (OSRAM)
RU (1) RU2008108219A (OSRAM)
TW (1) TW200800976A (OSRAM)
UA (1) UA92503C2 (OSRAM)
UY (1) UY29796A1 (OSRAM)
WO (1) WO2007040982A1 (OSRAM)
ZA (1) ZA200802163B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532869A (ja) * 2019-05-15 2022-07-20 スーリン、クラース 動物の疼痛の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン
JP2023501114A (ja) * 2019-11-05 2023-01-18 スーリン、クラース 哺乳動物の過労の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL375256A1 (en) * 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
KR20100090777A (ko) 2007-10-19 2010-08-17 아스트라제네카 아베 대사성 글루타메이트 수용체 (ｍｇｌｕｒ)의 조절제로서의 테트라졸 유도체
CN101918399A (zh) * 2007-10-26 2010-12-15 阿斯利康(瑞典)有限公司 作为mglur5调节剂的氨基1,2,4-三唑衍生物
TW201011016A (en) * 2008-08-12 2010-03-16 Astrazeneca Ab New compounds 501
JP2011530589A (ja) * 2008-08-12 2011-12-22 アストラゼネカ・アクチエボラーグ ４−（５−｛（１ｒ）−１−［５−（３−クロロフェニル）イソオキサゾール−３−イル］エトキシ｝−４−メチル−４ｈ−１，２，４−トリアゾール−３−イル）ピリジンの新規な結晶形態
AU2009307825A1 (en) * 2008-10-22 2010-04-29 Rick FRIEDMAN Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
JP2012511570A (ja) * 2008-12-12 2012-05-24 アストラゼネカ・アクチエボラーグ ４−［４−メチル−５−（ｃ１−１０アルキルチオ／ｃ５−１０アリール−ｃ１−６アルキルチオ）−４ｈ−１，２，４−トリアゾール−３−イル］ピリジンの新規製造方法
CN102256967A (zh) * 2008-12-18 2011-11-23 阿斯利康(瑞典)有限公司 制备3-{4-甲基-5-[(1r)-1-(2-(3-甲基苯基-2h-四唑-5-基)-乙氧基]-4h-[1,2,4]三唑-3-基}-吡啶、4-甲基-3-甲基硫基-5-(吡啶-3-基)-1,2,4-三唑和(1r)-1-[2-(3-甲基苯基)-2h-四唑-5-基]乙醇的方法
MX2011005982A (es) * 2008-12-18 2011-06-27 Astrazeneca Ab Nuevo proceso para preparar 1-[5-(3-clorofenil)isoxazol-3-il]etano na y (r)-1-[5-(3-clorofenil)isoxazol-3-il]etanol.
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8883827B2 (en) 2009-06-05 2014-11-11 Oslo University Hospital Hf Azole derivatives as WTN pathway inhibitors
CA2784768C (en) 2009-12-29 2015-02-03 Eli Lilly And Company Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
UA112418C2 (uk) * 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
JP2013544874A (ja) 2010-12-08 2013-12-19 オスロ ユニヴァーシティー ホスピタル エイチエフ Ｗｎｔシグナル伝達経路阻害薬としてのトリアゾール誘導体
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
WO2016163754A1 (en) * 2015-04-07 2016-10-13 Medpacto Inc. Pharmaceutical composition for preventing or treating cancer and method using thereof
KR20160120157A (ko) 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
CA3250533A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TREATING EXCESS GLUCOCORTICOIDS
WO2024088712A1 (en) 2022-10-28 2024-05-02 Orphelion Ab Mglur5 receptor antagonists for use in prevention and/or treatment of bone marrow lesions (bml) and/or osteoporosis, cartilage loss, osteosclerosis, osteitis in a mammal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202757A3 (en) 1999-08-19 2006-03-28 Nps Pharmaceuticals Inc Salt L Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists
UA74419C2 (uk) 2001-02-21 2005-12-15 Ен Пі Ес Фармасьютікалс, Інк. Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
US20040132726A1 (en) 2002-08-09 2004-07-08 Astrazeneca Ab And Nps Pharmaceuticals, Inc. New compounds
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
WO2005060971A1 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
CN1906187A (zh) 2003-12-19 2007-01-31 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5配体的5－氟－,氯－和氰基－吡啶－2－基－四唑类化合物
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
CA2556268A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
UA85576C2 (ru) 2004-02-18 2009-02-10 Астразенека Аб Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
SI1716152T1 (sl) 2004-02-18 2008-12-31 Astrazeneca Ab Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
RU2006127575A (ru) 2004-02-18 2008-03-27 Астразенека Аб (Se) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
NZ548693A (en) 2004-02-18 2010-05-28 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"新医薬品の規格及び試験方法の設定について", 医薬審発第５６８号, JPN6010021254, 2001, ISSN: 0002248822 *
長瀬博監訳, 最新 創薬化学 下巻, JPN6008054607, 25 September 1999 (1999-09-25), JP, pages 347 - 365, ISSN: 0002248823 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532869A (ja) * 2019-05-15 2022-07-20 スーリン、クラース 動物の疼痛の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン
JP7444901B2 (ja) 2019-05-15 2024-03-06 スーリン、クラース 動物の疼痛の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン
JP2023501114A (ja) * 2019-11-05 2023-01-18 スーリン、クラース 哺乳動物の過労の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン
JP7579337B2 (ja) 2019-11-05 2024-11-07 スーリン、クラース 哺乳動物の過労の予防及び／又は治療に使用するための４－［５－［（ｒａｃ）－１－［５－（３－クロロフェニル）－３－イソキサゾリル］エトキシ］－４－メチル－４ｈ－１，２，４－トリアゾール－３－イル］ピリジン

Also Published As

Publication number Publication date
ECSP088283A (es) 2008-04-28
ZA200802163B (en) 2009-09-30
IL189990A0 (en) 2008-08-07
US20070270469A1 (en) 2007-11-22
US7476684B2 (en) 2009-01-13
US20070129408A1 (en) 2007-06-07
UY29796A1 (es) 2007-04-30
US20070270468A1 (en) 2007-11-22
UA92503C2 (ru) 2010-11-10
TW200800976A (en) 2008-01-01
JP2010013476A (ja) 2010-01-21
CA2623009A1 (en) 2007-04-12
RU2008108219A (ru) 2009-11-10
KR20080050421A (ko) 2008-06-05
CN101273037A (zh) 2008-09-24
BRPI0616228A2 (pt) 2011-06-14
US20080227824A1 (en) 2008-09-18
AR058807A1 (es) 2008-02-27
NO20081434L (no) 2008-05-19
WO2007040982A1 (en) 2007-04-12
AU2006297462A1 (en) 2007-04-12
EP1934209A1 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
JP2010013476A (ja) 神経障害、精神障害または疼痛性障害の処置用の新規化合物
JP2011500673A (ja) 代謝調節型グルタミン酸受容体（ｍｇｌｕｒｓ）の調節因子としてのテトラゾール誘導体
US20090111824A1 (en) Amide linked heteroaromatic derivatives as modulators of mglur5
KR20090009952A (ko) Ｍｇｌｕｒ５ 조절제 ｉ
JP2009536211A (ja) Ｍｇｌｕｒ５モジュレーターｉｉｉ
JP2007523181A (ja) ポリヘテロ環式化合物、および、代謝型グルタミン酸受容体アンタゴニストとしてのそれらの使用
KR20090060328A (ko) Ｍｇｌｕｒ５ 조절제
JP2009536214A (ja) 縮合複素環化合物及びｍｇｌｕｒ５モジュレーターとしてのその使用
JP2009536212A (ja) 多環式複素環化合物及び代謝調節型グルタミン酸５受容体の調節剤としてのその使用
JP2009536210A (ja) Ｍｇｌｕｒ５モジュレーターｉｉ
KR20100089091A (ko) Ｍｇｌｕｒ5의 조절제로서의 아미노 1,2,4-트리아졸 유도체
US20090111820A1 (en) Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
KR20030097886A (ko) 신규 피페리딘카르복스아미드 유도체, 이의 제조 방법 및이를 함유하는 제약 조성물
US20100273805A1 (en) Sulphide bridged derivatives as modulators of mglur5 733
US20090111823A1 (en) Aminopyridine derivatives as modulators of mglur5

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090914

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121130